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Abstract
Background: Argininemia is an autosomal recessive urea cy-
cle disorder (UCD). Unlike other UCD, hyperammonemia is 
rarely seen. Patients usually present in childhood with neu-
rological symptoms. Uncommon presentations like neona-
tal cholestasis or cirrhosis have been reported. Although 
transient elevations of liver transaminases and coagulopa-
thy have been reported during hyperammonemia episodes, 
a permanent coagulopathy has never been reported. Meth-
ods: In this retrospective study, coagulation disturbances 
are examined in 6 argininemia patients. All of the patients 
were routinely followed up for hepatic involvement due to 
argininemia. Laboratory results, including liver transaminas-
es, albumin, prothrombin time (PT), international normal-
ized ratio (INR), activated partial thromboplastin time (aPTT), 
and clotting factor levels, were assessed in all of the patients. 
Results: All of the patients had a prolonged PT and an in-
creased INR, while none of the patients had a prolonged 
aPTT. Five patients had slightly elevated liver transaminases. 
A liver biopsy was performed in 1 patient but neither cirrho-
sis nor cholestasis was documented. Five of the 6 patients 
had low factor VII and factor IX levels, while other clotting 
factors were normal. Conclusions: Argininemia patients 
should be investigated for coagulation disorders even if 
there is no apparent liver dysfunction or major bleeding 
symptoms. © 2018 S. Karger AG, Basel
Introduction
Argininemia is an autosomal recessive disease caused 
by a defect in arginase 1 (ARG1), an enzyme involved in 
the urea cycle. Three urea cycle enzymes, i.e., N-acetyl-
glutamate synthase, carbamoyl phosphate synthetase 1, 
and ornithine transcarbamylase (OTC), are located in 
mitochondria, while the latter 3 enzymes, i.e., arginino-
succinic acid synthetase, argininosuccinic acid lyase, and 
ARG1, are expressed in the cytosol [1]. ARG1, as the final 
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step of the urea cycle, catalyzes the conversion of arginine 
to urea that is excreted in urine, and ornithine that par-
ticipates in the cycle. ARG1 deficiency (ARG1D, OMIM 
#207800) is a very rare disorder, with a reported esti-
mated incidence rate between 1/365,000 and 1/2,000,000 
[1–4].
Different from all of other urea cycle disorders (UCD), 
neonatal or early infantile onset disease with hyperam-
monemic decompensation is rarely seen in ARG1D [1, 2, 
5]. Classic clinical manifestations of the disease are spas-
tic paraparesis, mental retardation, failure to thrive, and 
episodic hyperammonemia, mostly starting in early 
childhood [2, 6]. Uncommon presentations of ARG1D 
with neonatal cholestasis or cirrhosis have been reported 
[7, 8, 9]. Transient elevations of liver transaminases and 
coagulopathy have been reported during episodes of hy-
perammonemia, but a permanent coagulopathy has nev-
er been reported [1, 2, 6]. 
Here we present 6 ARG1D patients who were all af-
fected by coagulation disturbances that were detected 
during routine investigations for hepatic involvement of 
argininemia.
Methods
All of the patients were followed up at the Pediatric Nutrition 
and Metabolic Disorders Clinic of the Cerrahpasa Medical Faculty 
in Istanbul, Turkey. Medical data were collected retrospectively 
from patients’ charts. Data collection included: age at diagnosis, 
current age, gender, consanguinity, history of neonatal cholestasis, 
and major-minor bleeding history (Table 1). 
The collected data included liver transaminases (alanine ami-
notransferase and aspartate aminotransferase), γ-glutamyl trans-
ferase, alkaline phosphatase, albumin, PT, INR, aPTT, and clotting 
factor levels. Clotting factor assays were performed as 1-stage clot-
ting-based tests using commercial plasma deficient of the relevant 
factor on different coagulation analyzers (BCT, BCS of Dade-Beh-
ring/Siemens or CA-1500 of Sysmex) depending on the availabil-
ity. Mutation analysis of the ARG1 gene was performed by stan-
dard Sanger sequencing of single exons with flanking intronic re-
gions. The laboratory results and the ARG1 mutation analysis are 
shown in Table 2.
Results
Six patients with argininemia were enrolled into this 
study. One patient was diagnosed by family screening fol-
lowing the diagnosis of an affected sibling (patient 2). The 
remaining patients were diagnosed via a selective meta-
bolic workup for neuromotor retardation. All of the pa-
tients had severe psychomotor retardation with spastic 
diplegia at the time of diagnosis. Patient 3 was also diag-
nosed with type 1 hyperlipidemia, with plasma triglycer-
ide values ranging between 999 and 2,100 mg/dL. Mo-
lecular analysis of the ARG1 gene was compatible with 
argininemia in 5 of the 6 patients, whereas patient 3 did 
not give consent for mutation analysis. All of the patients 
were routinely followed up for hepatic involvement due 
to ARG1D. Three patients (patients 1, 2, and 3) had mi-
nor bleeding findings (petechiae and ecchymosis) that 
were detected on routine physical examination, and 2 pa-
tients (patients 4 and 6) had abnormal laboratory findings 
noticed during preoperative testing. PT was prolonged 
and INR was increased, while aPTT was normal in all of 
the patients. Five patients had slightly elevated liver trans-
aminases. Patient 4 had markedly elevated transaminases; 
a liver biopsy was performed but neither liver cirrhosis 
nor cholestasis was documented. Five of the 6 patients 
had low factor VII and factor IX levels, while other clot-
ting factors were normal. Details of clinical characteris-
tics and laboratory findings are summarized in Tables 1 
and 2.
Table 1. Clinical characteristics of argininemia patients
Patient 
No.
Age at 
diagnosis, 
years
Age, 
years 
Gender Consan-
guinity
Neonatal 
cholestasis
Major 
bleeding
Minor bleeding Physical examination
1 7 13 Female Yes No No Yes (petechia) Spasticity, mental retardation
2 2 7 Female Yes No No Yes (petechia) Spasticity, mental retardation, epilepsy
3 4 12 Male Yes No No Yes (petechia, 
ecchymosis)
Spasticity, mental retardation
4 6 8 Female Yes No No No Spasticity, mental retardation 
5 5 7 Female Yes No No No Spasticity, mental retardation 
6 17 17 Male Yes No No No Spasticity, mental retardation, epilepsy
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Discussion
Argininemia due to ARG1D is the least common UCD, 
along with N-acetyl-glutamate synthase and CPS defi-
ciencies. Unlike other UCD, hyperammonemia episodes 
and neonatal presentations are uncommon in arginin-
emia. The classical presentation of the disease is charac-
terized by progressive neurologic impairment in early 
childhood after an apparently normal development. The 
exact mechanism of the central nervous system injury is, 
however, still not fully understood. Direct toxic effects of 
elevated arginine and arginine metabolites including gua-
nido components and nitric oxide have been suggested to 
be responsible for neurotoxicity [10, 11]. Besides the neu-
rologic involvement, extraneurological symptoms are 
also present and the liver is the main affected organ. He-
patic involvement in argininemia can vary from mild he-
patocellular injury with transient elevations of liver trans-
aminases to coagulation abnormalities and hepatic failure 
as in other UCD [7–9, 12].
Here we present 6 patients with argininemia and co-
agulation disturbances. The coagulation abnormalities 
were detected during routine investigations for hepatic 
involvement of argininemia or before surgical proce-
dures. All of our patients had mild to severe hepatic in-
volvement with elevation of liver transaminases, and only 
1 patient had mild hepatic fibrosis but no signs of hepatic 
failure were documented.
Data from the European registry of UCD show that 
highest frequency of liver disease is present in ASL and 
OTC deficiency among all UCD [13]. A recent study con-
firmed that neonatal histopathological changes in hepat-
ic involvement of UCD are nonspecific, whereas older pa-
tients develop variable hepatic fibrosis and focal changes 
resembling glycogen storage disorder and cirrhosis [14]. 
The exact mechanism of liver injury in UCD is not known. 
It has been claimed that hyperammonemia can lead to a 
decrease in hepatic protein synthesis and especially to a 
reduction of coagulation factors, which are liver-derived 
proteins with a short plasma half-life [15]. According to 
this study, OTC-deficient patients were observed to have 
decreased factor VII and concomitantly increased INR 
during hyperammonemia episodes [15]. Although hy-
perammonemia is not a constant finding of argininemia, 
additional factors that have not been described yet might 
play a role in liver damage. A recent case report showed 
no correlation between the coagulopathy and plasma am-
monia levels or with serum albumin levels, indicating the 
heterogeneous etiology of liver damage in OTC deficien-
cy [16]. In this study, none of our patients had hyperam-
monemia accompanying the coagulation abnormalities. 
The coagulation abnormalities of our patients were per-
Table 2. Laboratory findings of argininemia patients
Reference 
range
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Ammonia, µmol/L 11–60 18 23 46 43 31 48
PT, s 9.6–13.4 15.4–16.3 17.4–33.1 17.7–20 16.1–18.5 14.9–16.8 18.3
INR 0.9–1.2 1.39–1.48 1.48–3.48 1.53–1.73 1.48–2.21 1.37–1.62 1.46
aPTT, s 26–40.8 32.8–33.3 38–44.4 40.1–42.2 38.1–40.1 29.2–32.8 41.6
Platelet count, n × 103/mm3 100–300 135–154 199–227 258–303 114–176 233–264 237–270
Aspartate aminotransferase,
IU/L 0–40 43–70 48–118 28–50 52–374 42–66 40–45
Alanine aminotransferase, 
IU/L 0–40 41–55 62–175 15–30 56–281 44–119 41–46
γ-Glutamyl transferase, IU/L 3–25 7–11 10–13 9–11 17–31 11–18 12
Alkaline phosphatase, IU/L 60–525 114–256 350–515 126–205 300–381 135–173 388
Albumin, g/dL 3.2–5.2 4.3 3.9 3.8 4.1 3.6 4.2
Total bilirubin, mg/dL 0.3–1.2 0.5 0.5 0.4 0.3 0.3 0.4
Direct bilirubin, mg/dL 0–0.2 0.2 0.2 0.1 0.2 0.2 0.1
Factor II, % 50–150 79.4 62.7 72 69 69.3
Factor V, % 50–140 73.6 85.7 64 147 64.5
Factor VII, % 50–150 35.5 3.2–16.6 26 30.2 57.3 49.5
Factor VIII, % 50–150 82.3 112.6 70 78.6
Factor IX, % 50–150 32 19–29.8 38 17 67.3 36
Factor X, % 50–150 49.1 52.7 57 57.4 115.1 55
Mutation analyses Exon 2: c.61C>T 
(p.Arg21*) Exon 2: c.61C>T (p.Arg21*) Not performed Exon 2: c.61C>T (p.Arg21*) Intron 1: c.58-3C>G (splicing) Exon 4: c.446T>C (Leu149Pro)
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manent, independently of the patient’s metabolic status. 
Although coagulation abnormalities in urea cycle disor-
ders during hyperamonemia episodes have been well de-
scribed, plasma ammonia levels were found to be within 
the normal ranges at the time of blood sampling in all of 
the patients. As a result, coagulation abnormalities were 
not found to be associated with hyperammonemic epi-
sodes. Therefore, we suppose that coagulation abnormal-
ities are not correlated with hyperammonemia and addi-
tional mechanisms should play role in these patients.
Five of the 6 patients had low factor VII and factor IX 
levels, while other K vitamin-dependent factors like fac-
tors II and X were found to be normal. In order to rule 
out a vitamin K deficiency (factors VII and IX have the 
shortest half-lives among other vitamin K-dependent fac-
tors), parenteral vitamin K was attempted, with no im-
provement in coagulation parameters. Moreover, all of 
the patients had been on a low-protein diet with special 
formulas enriched with vitamin K1 and none of them was 
nasogastrically/gastrically fed. Also, none of our patients 
was hospitalized for any medication before coagulation 
parameters were tested and none had history of chronic 
use of any medication that could interfere with vitamin 
K, such as antibiotics or anticonvulsants, except for pa-
tient 2, who had been using levetiracetam. Unfortunately, 
PIVKA-II levels were not measured for subclinical vita-
min K deficiency.
Levels of factor V, which is synthesized only in liver and 
plasma albumin, were found to be within the normal ref-
erence ranges in all of the patients. As individual labora-
tory values which were accepted to be reliable indicators 
of synthetic liver function were obtained simultaneously 
with coagulation parameters and were found to be nor-
mal, it was thought that the factor VII and factor IX defi-
ciencies in our patients most probably did not result from 
the hepatic involvement of arginase deficiency [17, 18]. 
Interestingly, patient 5 had impaired coagulation param-
eters but no additional single-factor deficiency was identi-
fied. In addition, the existence of both factor VII and fac-
tor IX, which was observed in 5 of the 6 patients, excluded 
the congenital factor deficiencies in our ARG1D patients.
Despite the high incidence of coagulation disturbanc-
es, none of our patients had severe life-threating hemor-
rhages and only patients 1, 2, and 3 had minor bleeding 
problems such as petechia and ecchymosis detected dur-
ing a routine physical examination. Petechia and ecchy-
mosis are signs of primary hemorrhagic problems, indi-
cating that platelet associated or vascular problems might 
be present. Platelet counts and platelet morphologies 
were normal in our patients. As major bleeding symp-
toms were not observed in our patient group, advanced 
laboratory analyses to evaluate platelet functions were not 
performed.
In conclusion, we report the frequent observation of 
coagulation abnormalities in a small cohort of ARG1D 
patients and recommend investigating these patients for 
coagulation status even in the absence of an apparent liv-
er dysfunction or major bleeding symptoms. Due to the 
rarity of argininemia, it is difficult to study this disease in 
large patient cohorts, which would be required to find out 
whether coagulation factor deficiencies are common 
findings in ARG1D and whether they are related to hy-
perammonemia or other signs of liver dysfunction. Fur-
ther studies with large sample sizes and longer follow-up 
periods should elucidate the relationship and pathophys-
iological mechanisms of coagulopathy and argininemia. 
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